12:00 AM
 | 
Sep 13, 2010
 |  BC Week In Review  |  Company News  |  Sales & Marketing

SymBio, Eisai sales and marketing update

Eisai launched Symbenda bendamustine in Singapore to treat low-grade non-Hodgkin's lymphoma (NHL) and chronic lymphatic leukemia (CLL). SymBio, which has rights to the alkylating agent in Japan, China, Korea, Taiwan and...

Read the full 134 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >